MAZE stock forecast, quote, news & analysis
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity... Show more
Why Maze Therapeutics (MAZE) Is Down -34% in the Last 30 Days
Key Takeaways
- MAZE stock declined approximately -34% over the past 30 days, driven primarily by a sharp sell-off following positive Phase 2 HORIZON trial data for lead candidate MZE829, amid concerns over small sample size and mixed subgroup results.
- Over the past quarter, shares fell around -25%, reflecting broader biotech sector volatility despite positive clinical proof-of-concept and a strong cash position extending into 2028.
- Key factors include "sell-the-news" reaction to trial results, recent insider selling totaling over $5 million in shares, and high expectations not fully met in non-FSGS patients.
- Analysts remain bullish with "Buy" consensus and average price target above $60, citing best-in-class potential for MZE829 in APOL1-mediated kidney disease (AMKD).
- Q4 2025 earnings beat estimates with EPS of -$0.65 vs. consensus -$0.73, supporting pipeline advancement.
Maze Therapeutics (MAZE) Company Overview and Market Position
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney and metabolic diseases. The company's core business model leverages its proprietary Maze Compass platform, which uses human genetics and variant functionalization to identify and advance therapies targeting genetically defined patient populations.
Operating in the competitive biotechnology sector, Maze differentiates itself through programs like MZE829, an oral APOL1 (apolipoprotein L1) inhibitor for APOL1-mediated kidney disease (AMKD), and MZE782 for phenylketonuria (PKU) and chronic kidney disease (CKD). Its fundamentals, including partnerships with Shionogi & Co., Ltd. and Neurocrine Biosciences, Inc., provide validation and funding, helping explain recent stock behavior tied to clinical milestones rather than revenue generation.
Maze Therapeutics (MAZE) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MAZE stock dropped approximately -34%, from a closing price around $45 in early March to roughly $30 currently. The movement was highly volatile, peaking near $52 mid-month before plunging over 35% in a single session around late March, then stabilizing in the $29-$31 range amid elevated trading volume.
For the past quarter, shares declined about -25%, starting from approximately $40 in early January and exhibiting trend-driven downside with intermittent spikes linked to news events. The quarter featured range-bound trading in the mid-$40s before the sharp recent drop, contrasting broader biotech market trends.
What Drove MAZE Stock Price in the Last 30 Days
The primary catalyst was the March 25 announcement of positive topline data from the Phase 2 open-label HORIZON trial of MZE829, showing a 35.6% mean reduction in urinary albumin-to-creatinine ratio (uACR, a measure of proteinuria) at week 12 across 12 efficacy-evaluable patients with broad AMKD, including 50% achieving ≥30% reduction. While establishing clinical proof-of-concept and exceeding typical thresholds for kidney disease trials, the market reacted negatively due to the small cohort size (only 15 safety-evaluable patients) and perceived underwhelming results in non-focal segmental glomerulosclerosis (FSGS) subgroups, including those with diabetes.
This triggered a classic "sell-the-news" event, with shares plummeting 35% that day despite analyst praise for "best-in-class" potential versus competitors like Vertex Pharmaceuticals. Recent insider sales, including over $700,000 by executives in early March, added pressure amid high expectations baked into the pre-data price surge to $52.
Positive Q4 2025 earnings, beating EPS estimates and affirming a $360 million cash runway into 2028, provided limited offset as focus remained on trial details.
What Drove MAZE Stock Performance Over the Last Quarter
The quarter's -25% decline stemmed from sustained biotech sector pressures, including macroeconomic factors like interest rate sensitivity impacting unprofitable clinical-stage firms, and Maze-specific pipeline risks. Earlier optimism from a $150 million oversubscribed private placement in September 2025 and conference presentations fueled mid-quarter highs around $50.
Institutional investor behavior showed mixed signals, with some increases in holdings by firms like Janus Henderson offsetting insider sales totaling $5+ million. Competitive dynamics in the APOL1 inhibitor space, highlighted by regulatory discussions around focal segmental glomerulosclerosis (FSGS, a kidney scarring condition), influenced sentiment. Cumulative impact was dominated by pre-data anticipation building to a peak, followed by the volatile post-data correction.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from among hundreds that trade thousands of tickers across various markets. These curated bots are selected based on recent performance metrics, relevance to current market trends, and strategy diversity, including short-term scalping, swing trading, and long-term trend following. Each bot displays key statistics like win rate, average return, Sharpe ratio (a risk-adjusted performance measure), and drawdown, allowing users to evaluate suitability for different risk profiles and timeframes. Tickeron’s AI robots leverage machine learning to analyze vast datasets, adapting to volatility in stocks like MAZE. Explore the page to find bots tailored to biotech or volatile sectors and consider integrating them into your trading strategy today.
MAZE Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming Phase 2 initiations for MZE782 in PKU and CKD, expected in 2026, as well as detailed HORIZON data presentations. Pivotal trial planning for MZE829 in AMKD, including regulatory feedback on endpoints like uACR reduction, will be critical.
Industry trends in precision nephrology, such as APOL1 inhibitor competition and FDA guidance on FSGS, alongside macroeconomic conditions like interest rates affecting biotech funding, remain key. Strategic developments including partnership milestones with Shionogi and Neurocrine, plus Q1 2026 earnings, could sway sentiment. Risks involve trial enrollment delays or safety signals, while catalysts include analyst updates and institutional buying amid the current "Buy" consensus.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
MAZE's RSI Oscillator ascending out of oversold territory
The RSI Indicator for MAZE moved out of oversold territory on April 17, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 2 similar instances when the indicator left oversold territory. In of the 2 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for MAZE just turned positive on April 17, 2026. Looking at past instances where MAZE's MACD turned positive, the stock continued to rise in of 8 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MAZE advanced for three days, in of 71 cases, the price rose further within the following month. The odds of a continued upward trend are .
MAZE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on March 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MAZE as a result. In of 18 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
MAZE moved below its 50-day moving average on March 25, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MAZE crossed bearishly below the 50-day moving average on March 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 1 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MAZE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MAZE entered a downward trend on April 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MAZE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.758) is normal, around the industry mean (26.681). P/E Ratio (191.339) is within average values for comparable stocks, (45.953). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.776). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (500.000) is also within normal values, averaging (325.679).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MAZE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement